Drug Search Results
More Filters [+]

Broncho-vaxom

Alternative Names: broncho-vaxom, om-85, om85, om 85
Latest Update: 2024-10-23
Latest Update Note: Clinical Trial Update

Product Description

Broncho-Vaxom is effective and safe for the treatment of acute episodes of respiratory tract infections and for preventing recurrences.

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Brazil | Bulgaria | Chile | Czech | Egypt | Germany | Greece | Hungary | Indonesia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Switzerland | Turkey | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: OM Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Broncho-vaxom

Countries in Clinic: Australia, Germany, Hungary, Poland, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Dermatitis, Atopic|Other|Respiratory Sounds

Phase 1: Asthma, Allergic|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BV-2020/09

P2

Unknown Status

Other

2026-02-28

BV-2020/09

P2

Recruiting

Respiratory Sounds

2025-08-28

BV-2022/11

P1

Recruiting

Asthma, Allergic

2025-02-28

2021-003179-33

P2

Active, not recruiting

Dermatitis, Atopic

2024-03-29

Recent News Events